マルタ - 英語 - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - atorvastatin 30 mg - lipid modifying agents

マルタ - 英語 - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - atorvastatin 40 mg - lipid modifying agents

マルタ - 英語 - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - atorvastatin 60 mg - lipid modifying agents

マルタ - 英語 - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - atorvastatin 80 mg - lipid modifying agents

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - eptacog alfa (activated); histidine -

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 1mg - powder for injection with diluent - 1 mg - active: eptacog alfa (activated) 1mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 2mg - powder for injection with diluent - 2 mg - active: eptacog alfa (activated) 2mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 5mg - powder for injection with diluent - 5 mg - active: eptacog alfa (activated) 5mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 8mg;   - powder for injection with diluent - 8 mg - active: eptacog alfa (activated) 8mg   excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine accord is indicated for the treatment of patients with,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ,? chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), ,? acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), ,in whom allogenic stem cell transplantation is not indicated.